Report of the Cent Gardes HIV Vaccine Conference: The B-cell response to HIV Part 2: Non-neutralizing antibodies

Highlights • Protection in the RV144 efficacy trial was associated with HIV non-neutralizing antibodies. • Non-neutralizing HIV IgGs mediate antibody-dependent cellular cytotoxicity (ADCC). • Vaginal HIV IgAs, especially dIgA1, block virus transcytosis across monocellular epithelia. • HIV transcytos...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Vaccine 2013-06, Vol.31 (29), p.2984-2987
Hauptverfasser:	Girard, Marc P, Picot, Valentina, Longuet, Christophe, Nabel, Gary J
Format:	Artikel
Sprache:	eng
Schlagworte:	Acquired immune deficiency syndrome AIDS Allergy and Immunology Antibody-dependent cellular cytotoxicity Cytotoxicity HIV vaccines Immune system Immunization Infections Meetings Mucosal immunity Rodents Transcytosis inhibitory antibodies Vaccines
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • Protection in the RV144 efficacy trial was associated with HIV non-neutralizing antibodies. • Non-neutralizing HIV IgGs mediate antibody-dependent cellular cytotoxicity (ADCC). • Vaginal HIV IgAs, especially dIgA1, block virus transcytosis across monocellular epithelia. • HIV transcytosis is favored by acidic pH and the neonatal FcRn receptor.
ISSN:	0264-410X 1873-2518
DOI:	10.1016/j.vaccine.2013.02.067